NO20043101L - Farmasoytiske blandinger av oralt aktive taxanderivater som har forsterket biotilgjenglighet - Google Patents

Farmasoytiske blandinger av oralt aktive taxanderivater som har forsterket biotilgjenglighet

Info

Publication number
NO20043101L
NO20043101L NO20043101A NO20043101A NO20043101L NO 20043101 L NO20043101 L NO 20043101L NO 20043101 A NO20043101 A NO 20043101A NO 20043101 A NO20043101 A NO 20043101A NO 20043101 L NO20043101 L NO 20043101L
Authority
NO
Norway
Prior art keywords
orally active
enhanced bioavailability
taxane derivatives
pharmaceutical mixtures
active taxane
Prior art date
Application number
NO20043101A
Other languages
English (en)
Norwegian (no)
Inventor
Krishnaswamy Srinivas Raghavan
Sailesh Amilal Varia
Joseph B Bogardus
Robert K Perrone
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20043101L publication Critical patent/NO20043101L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20043101A 2001-12-20 2004-07-19 Farmasoytiske blandinger av oralt aktive taxanderivater som har forsterket biotilgjenglighet NO20043101L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34288901P 2001-12-20 2001-12-20
PCT/US2002/040127 WO2003053350A2 (en) 2001-12-20 2002-12-12 Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability

Publications (1)

Publication Number Publication Date
NO20043101L true NO20043101L (no) 2004-07-19

Family

ID=23343716

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20043101A NO20043101L (no) 2001-12-20 2004-07-19 Farmasoytiske blandinger av oralt aktive taxanderivater som har forsterket biotilgjenglighet

Country Status (24)

Country Link
US (1) US20030220391A1 (de)
EP (1) EP1465618A2 (de)
JP (1) JP2006501134A (de)
KR (1) KR20040066921A (de)
CN (1) CN1273130C (de)
AR (1) AR037951A1 (de)
AU (1) AU2002361701A1 (de)
BR (1) BR0215184A (de)
CA (1) CA2470826A1 (de)
GE (1) GEP20063806B (de)
HR (1) HRP20040545A2 (de)
HU (1) HUP0500843A2 (de)
IL (1) IL162118A0 (de)
IS (1) IS7306A (de)
MX (1) MXPA04005877A (de)
NO (1) NO20043101L (de)
PE (1) PE20030742A1 (de)
PL (1) PL374283A1 (de)
RS (1) RS52904A (de)
RU (1) RU2004119557A (de)
TW (1) TW200302086A (de)
UY (1) UY27598A1 (de)
WO (1) WO2003053350A2 (de)
ZA (1) ZA200404584B (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050063940A1 (en) * 2002-02-25 2005-03-24 Sveinbjorn Gizurarson Bioadhesive agent
US6855332B2 (en) * 2002-07-03 2005-02-15 Lyfjathroun Hf. Absorption promoting agent
KR100533458B1 (ko) 2002-07-20 2005-12-07 대화제약 주식회사 파클리탁셀의 가용화용 조성물 및 그의 제조 방법
EP1498120A1 (de) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Halbfeste Formulierung für die orale Verabreichung des Taxols
EP1785416A3 (de) 2003-09-25 2007-05-30 Tapestry Pharmaceuticals, Inc. 9, 10-Alpha, Alpha-OH-Taxan-Analogen und Herstellungsverfahren dafür
US20060088591A1 (en) * 2004-10-22 2006-04-27 Jinghua Yuan Tablets from a poorly compressible substance
WO2006058121A1 (en) * 2004-11-23 2006-06-01 Bristol-Myers Squibb Company Crystalline forms of 3'-tert-butyl-3'-n-tert-butyloxycarbonyl-4-deacetyl-3'-dephenyl-3'-n-debenzoyl-4-o-methoxycarbonyl-paclitaxel
US20090130163A1 (en) * 2005-02-18 2009-05-21 Abraxis Bio Scoence, Inc. Drugs With Improved Hydrophobicity For Incorporation in Medical Devices
AU2012202903B2 (en) * 2005-02-18 2014-12-11 Abraxis Bioscience, Inc. Drugs with improved hydrophobicity for incorporation in medical devices
JP5436856B2 (ja) * 2005-07-15 2014-03-05 アンジオケム インコーポレーティッド 薬学的複合体における担体としてのアプロチニンポリペプチドの使用
US20070015834A1 (en) * 2005-07-18 2007-01-18 Moshe Flashner-Barak Formulations of fenofibrate containing PEG/Poloxamer
BRPI0615265A8 (pt) 2005-08-31 2018-03-06 Abraxis Bioscience Llc composições compreendendo agentes farmacêuticos pouco hidrossoluíveis e agentes antimicrobianos
WO2007134354A1 (de) * 2006-05-23 2007-11-29 Ebewe Pharma Ges.M.B.H. Nfg. Kg Pharmazeutische formulierung
US11786504B2 (en) 2006-09-28 2023-10-17 Tapestry Pharmaceuticals, Inc. Taxane analogs for the treatment of brain cancer
WO2008121476A1 (en) 2007-03-28 2008-10-09 Tapestry Pharmaceuticals, Inc. Biologically active taxane analogs and methods of treatment by oral administration
US11873308B2 (en) 2006-11-06 2024-01-16 Tapestry Pharmaceuticals, Inc. Biologically active taxane analogs and methods of treatment by oral administration
EP1946747A1 (de) * 2007-01-17 2008-07-23 Sandoz AG Taxanderivat enthaltende pharmazeutische Zusammensetzung von verbesserter Stabilität
WO2008109360A1 (en) * 2007-02-28 2008-09-12 Tapestry Pharmaceuticals, Inc Taxane analogs for the treatment of brain cancer
MX2010002179A (es) * 2007-08-24 2010-04-27 Stichting Het Nl Kanker I Composicion para el tratamiento de enfermedades neoplasicas.
US9089544B2 (en) * 2007-08-24 2015-07-28 Slotervaart Participaties Bv Composition
RU2488393C2 (ru) * 2007-11-12 2013-07-27 Новартис Аг Жидкие композиции, включающие валсартан
EP2077132A1 (de) 2008-01-02 2009-07-08 Boehringer Ingelheim Pharma GmbH & Co. KG Abgabevorrichtung, Aufbewahrungsvorrichtung und Verfahren zur Abgabe einer Formulierung
ES2344674B1 (es) 2008-08-07 2011-06-29 Gp Pharm, S.A. Composicion farmaceutica inyectable de taxanos.
US8921314B2 (en) 2008-10-15 2014-12-30 Angiochem, Inc. Conjugates of GLP-1 agonists and uses thereof
EP2414560B1 (de) 2009-03-31 2013-10-23 Boehringer Ingelheim International GmbH Verfahren zur beschichtung einer oberfläche eines bauteils
EP3508239B1 (de) 2009-05-18 2020-12-23 Boehringer Ingelheim International GmbH Adapter, inhalationseinrichtung und zerstäuber
CN102038635A (zh) 2009-10-23 2011-05-04 天津天士力集团有限公司 一种含有pH值调节剂的紫杉烷类药物溶液及其制备方法
US10016568B2 (en) 2009-11-25 2018-07-10 Boehringer Ingelheim International Gmbh Nebulizer
MX2012005961A (es) 2009-11-25 2012-06-14 Boehringer Ingelheim Int Nebulizador.
JP5658268B2 (ja) 2009-11-25 2015-01-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ネブライザ
JP5874724B2 (ja) 2010-06-24 2016-03-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ネブライザ
WO2012130757A1 (de) 2011-04-01 2012-10-04 Boehringer Ingelheim International Gmbh Medizinisches gerät mit behälter
US9827384B2 (en) 2011-05-23 2017-11-28 Boehringer Ingelheim International Gmbh Nebulizer
WO2013152894A1 (de) 2012-04-13 2013-10-17 Boehringer Ingelheim International Gmbh Zerstäuber mit kodiermitteln
EP2777691A1 (de) * 2013-03-14 2014-09-17 Pharmachemie B.V. Taxoid - Reinigung der flüssigen Hilfsstoffen
WO2015018904A1 (en) 2013-08-09 2015-02-12 Boehringer Ingelheim International Gmbh Nebulizer
EP2835146B1 (de) 2013-08-09 2020-09-30 Boehringer Ingelheim International GmbH Zerstäuber
MX383195B (es) 2014-05-07 2025-03-13 Boehringer Ingelheim Int Recipiente, nebulizador y uso.
WO2015169430A1 (en) 2014-05-07 2015-11-12 Boehringer Ingelheim International Gmbh Nebulizer
BR122022010094B1 (pt) 2014-05-07 2023-10-03 Boehringer Ingelheim International Gmbh Dispositivo indicador e recipiente
CN103980232A (zh) * 2014-06-05 2014-08-13 北京诺普德医药科技有限公司 10-乙酰基多西紫杉醇及其用途
US10980892B2 (en) 2015-06-15 2021-04-20 Angiochem Inc. Methods for the treatment of leptomeningeal carcinomatosis
TWI715636B (zh) * 2015-09-30 2021-01-11 香港商慧源香港創新有限公司 口服紫杉烷組合物及方法
CN108066335B (zh) * 2016-11-11 2020-02-21 北京康辰药业股份有限公司 一种含有紫杉醇或其类似物的药物组合物及其制备方法
FR3113238B1 (fr) 2020-08-05 2024-04-05 Gattefosse Sas Utilisation comme excipient, d’un melange de macrogolglyceride laurique et de polyethylene glycol

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US4960790A (en) * 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
US5817321A (en) * 1992-10-08 1998-10-06 Supratek Pharma, Inc. Biological agent compositions
ES2224200T3 (es) * 1992-11-27 2005-03-01 Mayne Pharma (Usa) Inc. Composicion inyectable estable de paclitaxel.
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
US6395770B1 (en) * 1995-10-26 2002-05-28 Baker Norton Pharmaceuticals, Inc. Method and compositions for administering taxanes orally to human patients
US6964946B1 (en) * 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
US5977163A (en) * 1996-03-12 1999-11-02 Pg-Txl Company, L. P. Water soluble paclitaxel prodrugs
CA2189916C (en) * 1996-11-08 2001-01-16 Parkash S. Gill A new regime for paclitaxel in kaposi's sarcoma patients
US6515016B2 (en) * 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6495579B1 (en) * 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US5980936A (en) * 1997-08-07 1999-11-09 Alliance Pharmaceutical Corp. Multiple emulsions comprising a hydrophobic continuous phase
HUP0101457A3 (en) * 1997-12-31 2003-01-28 Bristol Myers Squibb Co Antitumor 2-aroyl-4-acyl paclitaxel analogs and medicaments containing them , their intermediates and method for producing them
IL131217A0 (en) * 1998-03-10 2001-01-28 Napro Biotherapeutics Inc Novel methods and compositions for delivery of taxanes
US6979456B1 (en) * 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
IL144976A0 (en) * 1999-05-17 2002-06-30 Bristol Myers Squibb Co A process for the preparation of paclitaxel
DE60010476T2 (de) * 1999-08-11 2005-04-14 Bristol-Myers Squibb Co. Verfahren zur Herstellung eines C-4-Methylcarbonat-Analogons von Paclitaxel
US6136846A (en) * 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
US6750246B1 (en) * 2000-02-03 2004-06-15 Bristol-Myers Squibb Company C-4 carbonate taxanes
US6916942B2 (en) * 2000-02-03 2005-07-12 Bristol-Myers Squibb Company Process for the preparation of C-4 carbonate taxanes
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
EP1337273A2 (de) * 2000-11-28 2003-08-27 Transform Pharmaceuticals, Inc. Pharmazeutische zusammensetzungen enthaltend paclitaxel, dessen derivate und dessen pharmazeutisch denkbare saltze
TWI297335B (en) * 2001-07-10 2008-06-01 Synta Pharmaceuticals Corp Taxol enhancer compounds
AU2002357012A1 (en) * 2001-11-27 2003-06-10 Transform Pharmaceuticals, Inc. Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof

Also Published As

Publication number Publication date
AU2002361701A1 (en) 2003-07-09
ZA200404584B (en) 2005-09-13
CA2470826A1 (en) 2003-07-03
IS7306A (is) 2004-06-10
RU2004119557A (ru) 2005-04-20
HUP0500843A2 (hu) 2005-12-28
WO2003053350A2 (en) 2003-07-03
PL374283A1 (en) 2005-10-03
HRP20040545A2 (en) 2005-08-31
KR20040066921A (ko) 2004-07-27
CN1606437A (zh) 2005-04-13
UY27598A1 (es) 2003-07-31
PE20030742A1 (es) 2003-09-02
RS52904A (sr) 2006-12-15
WO2003053350A3 (en) 2004-01-15
TW200302086A (en) 2003-08-01
MXPA04005877A (es) 2004-09-13
GEP20063806B (en) 2006-04-25
AR037951A1 (es) 2004-12-22
JP2006501134A (ja) 2006-01-12
BR0215184A (pt) 2006-06-06
CN1273130C (zh) 2006-09-06
US20030220391A1 (en) 2003-11-27
EP1465618A2 (de) 2004-10-13
IL162118A0 (en) 2005-11-20

Similar Documents

Publication Publication Date Title
MXPA04005877A (es) Composiciones farmaceuticas de derivados de taxano oralmente activos con biodisponibilidad mejorada.
CY1115386T1 (el) Συνδυασμος αζελαστινης και μομεταζονης
NO2016005I1 (no) 2-okso-1-pyrrolidinderivater, farmasøytisk preparat og deres anvendelse for fremstilling av et medikament
LU92513I2 (fr) Sofosbuvir et ses dérivés pharmaceutiquement acceptables (solvaldi)
NO20075660L (no) Blanding for behandling av inflammatoriske sykdommer
NO2012006I2 (no) Telaprevir og enhver terapeutisk ekvivalent form derav som er beskyttet av basispatentet, slik som farmasøytisk akseptable salter og/eller solvater av telaprevir eller solvater av slike salter
NO20035438L (no) Farmasoytisk formulering for effektiv administrering av apomorfin, 6aR-(-)-N-propyl-norapomorfin og deres derivater og prodrugs derav
DK1498411T3 (da) Diketohydrazinderivatforbindelser og medikamenter indeholdende forbindelserne som den aktive bestanddel
CY1113462T1 (el) Μορφη δοσολογιας περιεχουσα παντοπραζολη ως δραστικο συστατικο
SG147450A1 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
CO5590918A2 (es) Formulaciones
DK1675591T3 (da) Farmaceutisk sammensætning omfattende en monoamin-neurotransmitter-genoptagelseshæmmer og en acetylcholinesterase-hæmmer
CY1108676T1 (el) Οφθαλμικο εναιωρημα περιλαμβανον ενα οφθαλμικο φαρμακο, μια πολοξαμινη και εναν παραγοντα ρυθμισεως της τονικοτητας τυπου γλυκολης, χρηση της εν λογω συνθεσεως για την παραγωγη ενος φαρμακου για την αγωγη οφθαλμικων διαταραχων
EP1574215A4 (de) Feste arznei zur oralen verabreichung
NO20021050L (no) Nye derivater av flavoner, xantoner og kumariner
SE0101932D0 (sv) Pharmaceutical combinations
DK1379508T3 (da) N-(aryl)-2arylethensulfonamider og terapeutiske anvendelser deraf
EA200600603A1 (ru) Оральная система доставки лекарственного препарата
DK1992338T3 (da) Pharmaceutical compositions for the oral administration of heparin or derivatives thereof
NO20061702L (no) Farmasoytiske sammensetninger og fremgangsmater omfattende kombinasjoner av 2-alkyliden-19-nor-vitamin D derivater og en ostrogen agonist/antagonist
NO20043314L (no) Sedative non-benzodiazepinformuleringer
NO20062668L (no) Orale formuleringer av desoxypeganin og anvendelser derav
WO2004062564A3 (en) Sedative non-benzodiazepine formulations
EA200602199A1 (ru) Композиции, содержащие глюкозаминогликан и нестероидное противовоспалительное средство
EE200300465A (et) Püridoindolooni derivaatidel põhinevad farmatseutilised kompositsioonid

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application